<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36555377</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>24</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>12</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>High Dose Pharmaceutical Grade Biotin (MD1003) Accelerates Differentiation of Murine and Grafted Human Oligodendrocyte Progenitor Cells In Vivo.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">15733</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms232415733</ELocationID><Abstract><AbstractText>Accumulating evidences suggest a strong correlation between metabolic changes and neurodegeneration in CNS demyelinating diseases such as multiple sclerosis (MS). Biotin, an essential cofactor for five carboxylases, is expressed by oligodendrocytes and involved in fatty acid synthesis and energy production. The metabolic effect of biotin or high-dose-biotin (MD1003) has been reported on rodent oligodendrocytes in vitro, and in neurodegenerative or demyelinating animal models. However, clinical studies, showed mild or no beneficial effect of MD1003 in amyotrophic lateral sclerosis (ALS) or MS. Here, we took advantage of a mouse model of myelin deficiency to study the effects of MD1003 on the behavior of murine and grafted human oligodendrocytes in vivo. We show that MD1003 increases the number and the differentiation potential of endogenous murine oligodendroglia over time. Moreover, the levels of MD1003 are increased in the plasma and brain of pups born to treated mothers, indicating that MD1003 can pass through the mother's milk. The histological analysis of the grafted animals shows that MD1003 increased proliferation and accelerates differentiation of human oligodendroglia, but without enhancing their myelination potential. These findings provide important insights into the role of MD1003 on murine and human oligodendrocyte maturation/myelination that may explain the mitigated outcome of ALS/MS clinical trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Marion J F</ForeName><Initials>MJF</Initials><AffiliationInfo><Affiliation>INSERM, U1127, 75013 Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CNRS, UMR 7225, 75013 Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Sorbonne Universit&#xe9;, UPMC Paris 06, UM-75, 75005 Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>GH Piti&#xe9;-Salp&#xea;tri&#xe8;re, Institut du Cerveau (ICM), 75013 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia-Diaz</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-2655-571X</Identifier><AffiliationInfo><Affiliation>INSERM, U1127, 75013 Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CNRS, UMR 7225, 75013 Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Sorbonne Universit&#xe9;, UPMC Paris 06, UM-75, 75005 Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>GH Piti&#xe9;-Salp&#xea;tri&#xe8;re, Institut du Cerveau (ICM), 75013 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sedel</LastName><ForeName>Fr&#xe9;d&#xe9;ric</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>MedDay Pharmaceuticals SA, 75008 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baron-Van Evercooren</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>INSERM, U1127, 75013 Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CNRS, UMR 7225, 75013 Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Sorbonne Universit&#xe9;, UPMC Paris 06, UM-75, 75005 Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>GH Piti&#xe9;-Salp&#xea;tri&#xe8;re, Institut du Cerveau (ICM), 75013 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mozafari</LastName><ForeName>Sabah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>INSERM, U1127, 75013 Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CNRS, UMR 7225, 75013 Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Sorbonne Universit&#xe9;, UPMC Paris 06, UM-75, 75005 Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>GH Piti&#xe9;-Salp&#xea;tri&#xe8;re, Institut du Cerveau (ICM), 75013 Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MedDay Pharmaceuticals SA, 75008 Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratoire Mati&#xe8;re et Syst&#xe8;me Complexe, MSC-Med, CNRS, UMR 7057, Universit&#xe9; de Paris Cit&#xe9;, 75006 Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ANR-11-INBS-0011</GrantID><Agency>INBS NeurATRIS</Agency><Country/></Grant><Grant><GrantID>ARSEP #1259</GrantID><Agency>French Multiple Sclerosis Foundation</Agency><Country/></Grant><Grant><GrantID>ICM contract</GrantID><Agency>MedDay Pharmaceuticals</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>6SO6U10H04</RegistryNumber><NameOfSubstance UI="D001710">Biotin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001710" MajorTopicYN="Y">Biotin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="Y">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009186" MajorTopicYN="N">Myelin Sheath</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073637" MajorTopicYN="Y">Oligodendrocyte Precursor Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009836" MajorTopicYN="N">Oligodendroglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">MD1003</Keyword><Keyword MajorTopicYN="N">human oligodendrocytes</Keyword><Keyword MajorTopicYN="N">humanized animal model</Keyword><Keyword MajorTopicYN="N">murine oligodendrocytes</Keyword><Keyword MajorTopicYN="N">myelination</Keyword><Keyword MajorTopicYN="N">oligodendrocyte differentiation</Keyword><Keyword MajorTopicYN="N">shiverer mice</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>23</Day><Hour>1</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36555377</ArticleId><ArticleId IdType="pmc">PMC9778913</ArticleId><ArticleId IdType="doi">10.3390/ijms232415733</ArticleId><ArticleId IdType="pii">ijms232415733</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jitrapakdee S., Wallace J.C. The biotin enzyme family: Conserved structural motifs and domain rearrangements. Curr. Protein Pept. Sci. 2003;4:217&#x2013;229. doi: 10.2174/1389203033487199.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389203033487199</ArticleId><ArticleId IdType="pubmed">12769720</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuroishi T. Regulation of immunological and inflammatory functions by biotin. Can. J. Physiol. Pharmacol. 2015;93:1091&#x2013;1096. doi: 10.1139/cjpp-2014-0460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1139/cjpp-2014-0460</ArticleId><ArticleId IdType="pubmed">26168302</ArticleId></ArticleIdList></Reference><Reference><Citation>Saleem H., Simpson B. StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2022. Biotinidase Deficiency.</Citation><ArticleIdList><ArticleId IdType="pubmed">32809442</ArticleId></ArticleIdList></Reference><Reference><Citation>Bottin L., Prud&#x2019;hon S., Guey S., Giannesini C., Wolf B., Pindolia K., Stankoff B. Biotinidase deficiency mimicking neuromyelitis optica: Initially exhibiting symptoms in adulthood. Mult. Scler. 2015;21:1604&#x2013;1607. doi: 10.1177/1352458515596457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458515596457</ArticleId><ArticleId IdType="pubmed">26203071</ArticleId></ArticleIdList></Reference><Reference><Citation>Lohr K.M., Frost B., Scherzer C., Feany M.B. Biotin rescues mitochondrial dysfunction and neurotoxicity in a tauopathy model. Proc. Natl. Acad. Sci. USA. 2020;117:33608&#x2013;33618. doi: 10.1073/pnas.1922392117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1922392117</ArticleId><ArticleId IdType="pmc">PMC7777082</ArticleId><ArticleId IdType="pubmed">33318181</ArticleId></ArticleIdList></Reference><Reference><Citation>Pindolia K., Chen J., Cardwell C., Cui X., Chopp M., Wolf B. Neurological deficits in mice with profound biotinidase deficiency are associated with demylination and axonal degeneration. Neurobiol. Dis. 2012;47:428&#x2013;435. doi: 10.1016/j.nbd.2012.04.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2012.04.016</ArticleId><ArticleId IdType="pmc">PMC3970768</ArticleId><ArticleId IdType="pubmed">22579707</ArticleId></ArticleIdList></Reference><Reference><Citation>Fok-Seang J., Miller R.H. Distribution and differentiation of A2B5+ glial precursors in the developing rat spinal cord. J. Neurosci. Res. 1994;37:219&#x2013;235. doi: 10.1002/jnr.490370208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.490370208</ArticleId><ArticleId IdType="pubmed">8151730</ArticleId></ArticleIdList></Reference><Reference><Citation>Barateiro A., Brites D., Fernandes A. Oligodendrocyte Development and Myelination in Neurodevelopment: Molecular Mechanisms in Health and Disease. Curr. Pharm. Des. 2016;22:656&#x2013;679. doi: 10.2174/1381612822666151204000636.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1381612822666151204000636</ArticleId><ArticleId IdType="pubmed">26635271</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumann N., Pham-Dinh D. Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol. Rev. 2001;81:871&#x2013;927. doi: 10.1152/physrev.2001.81.2.871.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.2001.81.2.871</ArticleId><ArticleId IdType="pubmed">11274346</ArticleId></ArticleIdList></Reference><Reference><Citation>Salzer J.L. Polarized domains of myelinated axons. Neuron. 2003;40:297&#x2013;318. doi: 10.1016/S0896-6273(03)00628-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00628-7</ArticleId><ArticleId IdType="pubmed">14556710</ArticleId></ArticleIdList></Reference><Reference><Citation>Chamberlain K.A., Huang N., Xie Y., LiCausi F., Li S., Li Y., Sheng Z.H. Oligodendrocytes enhance axonal energy metabolism by deacetylation of mitochondrial proteins through transcellular delivery of SIRT2. Neuron. 2021;109:3456&#x2013;3472. doi: 10.1016/j.neuron.2021.08.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2021.08.011</ArticleId><ArticleId IdType="pmc">PMC8571020</ArticleId><ArticleId IdType="pubmed">34506725</ArticleId></ArticleIdList></Reference><Reference><Citation>Nave K.A., Trapp B.D. Axon-glial signaling and the glial support of axon function. Annu. Rev. Neurosci. 2008;31:535&#x2013;561. doi: 10.1146/annurev.neuro.30.051606.094309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.30.051606.094309</ArticleId><ArticleId IdType="pubmed">18558866</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklin R.J. Why does remyelination fail in multiple sclerosis? Nat. Rev. Neurosci. 2002;3:705&#x2013;714. doi: 10.1038/nrn917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn917</ArticleId><ArticleId IdType="pubmed">12209119</ArticleId></ArticleIdList></Reference><Reference><Citation>Harlow D.E., Honce J.M., Miravalle A.A. Remyelination Therapy in Multiple Sclerosis. Front. Neurol. 2015;6:257. doi: 10.3389/fneur.2015.00257.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2015.00257</ArticleId><ArticleId IdType="pmc">PMC4674562</ArticleId><ArticleId IdType="pubmed">26696956</ArticleId></ArticleIdList></Reference><Reference><Citation>Blakemore W.F., Irvine K.A. Endogenous or exogenous oligodendrocytes for remyelination. J. Neurol. Sci. 2008;265:43&#x2013;46. doi: 10.1016/j.jns.2007.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2007.08.004</ArticleId><ArticleId IdType="pubmed">17826797</ArticleId></ArticleIdList></Reference><Reference><Citation>Tepavcevic V., Lubetzki C. Oligodendrocyte progenitor cell recruitment and remyelination in multiple sclerosis: The more, the merrier? Brain. 2022:1&#x2013;15. doi: 10.1093/brain/awac307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac307</ArticleId><ArticleId IdType="pubmed">36093726</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklin R.J.M., Ffrench-Constant C. Regenerating CNS myelin&#x2014;From mechanisms to experimental medicines. Nat. Rev. Neurosci. 2017;18:753&#x2013;769. doi: 10.1038/nrn.2017.136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn.2017.136</ArticleId><ArticleId IdType="pubmed">29142295</ArticleId></ArticleIdList></Reference><Reference><Citation>Chanoumidou K., Mozafari S., Baron-Van Evercooren A., Kuhlmann T. Stem cell derived oligodendrocytes to study myelin diseases. Glia. 2020;68:705&#x2013;720. doi: 10.1002/glia.23733.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23733</ArticleId><ArticleId IdType="pubmed">31633852</ArticleId></ArticleIdList></Reference><Reference><Citation>Mozafari S., Baron-Van Evercooren A. Human stem cell-derived oligodendrocytes: From humanized animal models to cell therapy in myelin diseases. Semin. Cell Dev. Biol. 2021;116:53&#x2013;61. doi: 10.1016/j.semcdb.2020.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcdb.2020.09.011</ArticleId><ArticleId IdType="pubmed">33082116</ArticleId></ArticleIdList></Reference><Reference><Citation>Mozafari S., Starost L., Manot-Saillet B., Garcia-Diaz B., Xu Y.K.T., Roussel D., Levy M.J.F., Ottoboni L., Kim K.P., Scholer H.R., et al. Multiple sclerosis iPS-derived oligodendroglia conserve their properties to functionally interact with axons and glia in vivo. Sci. Adv. 2020;6:eabc6983. doi: 10.1126/sciadv.abc6983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abc6983</ArticleId><ArticleId IdType="pmc">PMC7821889</ArticleId><ArticleId IdType="pubmed">33277253</ArticleId></ArticleIdList></Reference><Reference><Citation>Melchor G.S., Khan T., Reger J.F., Huang J.K. Remyelination Pharmacotherapy Investigations Highlight Diverse Mechanisms Underlying Multiple Sclerosis Progression. ACS Pharmacol. Transl. Sci. 2019;2:372&#x2013;386. doi: 10.1021/acsptsci.9b00068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsptsci.9b00068</ArticleId><ArticleId IdType="pmc">PMC7088971</ArticleId><ArticleId IdType="pubmed">32259071</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidker R.M., Emerson M.R., LeVine S.M. Metabolic pathways as possible therapeutic targets for progressive multiple sclerosis. Neural Regen. Res. 2017;12:1262&#x2013;1267. doi: 10.4103/1673-5374.213542.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.213542</ArticleId><ArticleId IdType="pmc">PMC5607817</ArticleId><ArticleId IdType="pubmed">28966637</ArticleId></ArticleIdList></Reference><Reference><Citation>LeVine S.M., Macklin W.B. Biotin enrichment in oligodendrocytes in the rat brain. Brain Res. 1988;444:199&#x2013;203. doi: 10.1016/0006-8993(88)90930-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(88)90930-4</ArticleId><ArticleId IdType="pubmed">3359289</ArticleId></ArticleIdList></Reference><Reference><Citation>Sghaier R., Zarrouk A., Nury T., Badreddine I., O&#x2019;Brien N., Mackrill J.J., Vejux A., Samadi M., Nasser B., Caccia C., et al. Biotin attenuation of oxidative stress, mitochondrial dysfunction, lipid metabolism alteration and 7beta-hydroxycholesterol-induced cell death in 158N murine oligodendrocytes. Free Radic. Res. 2019;53:535&#x2013;561. doi: 10.1080/10715762.2019.1612891.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10715762.2019.1612891</ArticleId><ArticleId IdType="pubmed">31039616</ArticleId></ArticleIdList></Reference><Reference><Citation>Sedel F., Bernard D., Mock D.M., Tourbah A. Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis. Neuropharmacology. 2016;110:644&#x2013;653. doi: 10.1016/j.neuropharm.2015.08.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2015.08.028</ArticleId><ArticleId IdType="pubmed">26327679</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosko L., Smith V.N., Yamazaki R., Huang J.K. Oligodendrocyte Bioenergetics in Health and Disease. Neuroscientist. 2019;25:334&#x2013;343. doi: 10.1177/1073858418793077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1073858418793077</ArticleId><ArticleId IdType="pmc">PMC6745601</ArticleId><ArticleId IdType="pubmed">30122106</ArticleId></ArticleIdList></Reference><Reference><Citation>Fourcade S., Goicoechea L., Parameswaran J., Schluter A., Launay N., Ruiz M., Seyer A., Colsch B., Calingasan N.Y., Ferrer I., et al. High-dose biotin restores redox balance, energy and lipid homeostasis, and axonal health in a model of adrenoleukodystrophy. Brain Pathol. 2020;30:945&#x2013;963. doi: 10.1111/bpa.12869.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12869</ArticleId><ArticleId IdType="pmc">PMC8018149</ArticleId><ArticleId IdType="pubmed">32511826</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui Q.L., Lin Y.H., Xu Y.K.T., Fernandes M.G.F., Rao V.T.S., Kennedy T.E., Antel J. Effects of Biotin on survival, ensheathment, and ATP production by oligodendrocyte lineage cells in vitro. PLoS ONE. 2020;15:e0233859. doi: 10.1371/journal.pone.0233859.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0233859</ArticleId><ArticleId IdType="pmc">PMC7259710</ArticleId><ArticleId IdType="pubmed">32470040</ArticleId></ArticleIdList></Reference><Reference><Citation>Juntas-Morales R., Pageot N., Bendarraz A., Alphandery S., Sedel F., Seigle S., Camu W. High-dose pharmaceutical grade biotin (MD1003) in amyotrophic lateral sclerosis: A pilot study. EClinicalMedicine. 2020;19:100254. doi: 10.1016/j.eclinm.2019.100254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2019.100254</ArticleId><ArticleId IdType="pmc">PMC7046518</ArticleId><ArticleId IdType="pubmed">32140672</ArticleId></ArticleIdList></Reference><Reference><Citation>Tourbah A., Lebrun-Frenay C., Edan G., Clanet M., Papeix C., Vukusic S., De Seze J., Debouverie M., Gout O., Clavelou P., et al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. Mult. Scler. 2016;22:1719&#x2013;1731. doi: 10.1177/1352458516667568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458516667568</ArticleId><ArticleId IdType="pmc">PMC5098693</ArticleId><ArticleId IdType="pubmed">27589059</ArticleId></ArticleIdList></Reference><Reference><Citation>Collongues N., Kuhle J., Tsagkas C., Lamy J., Meyer N., Barro C., Parmar K., Amann M., Wuerfel J., Kappos L., et al. Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high-dose pharmaceutical-grade biotin (MD1003) Brain Behav. 2021;11:e01998. doi: 10.1002/brb3.1998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/brb3.1998</ArticleId><ArticleId IdType="pmc">PMC7882156</ArticleId><ArticleId IdType="pubmed">33314801</ArticleId></ArticleIdList></Reference><Reference><Citation>Cree B.A.C., Cutter G., Wolinsky J.S., Freedman M.S., Comi G., Giovannoni G., Hartung H.P., Arnold D., Kuhle J., Block V., et al. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2020;19:988&#x2013;997. doi: 10.1016/S1474-4422(20)30347-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30347-1</ArticleId><ArticleId IdType="pubmed">33222767</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrlich M., Mozafari S., Glatza M., Starost L., Velychko S., Hallmann A.L., Cui Q.L., Schambach A., Kim K.P., Bachelin C., et al. Rapid and efficient generation of oligodendrocytes from human induced pluripotent stem cells using transcription factors. Proc. Natl. Acad. Sci. USA. 2017;114:E2243&#x2013;E2252. doi: 10.1073/pnas.1614412114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1614412114</ArticleId><ArticleId IdType="pmc">PMC5358375</ArticleId><ArticleId IdType="pubmed">28246330</ArticleId></ArticleIdList></Reference><Reference><Citation>Mozafari S., Laterza C., Roussel D., Bachelin C., Marteyn A., Deboux C., Martino G., Baron-Van Evercooren A. Skin-derived neural precursors competitively generate functional myelin in adult demyelinated mice. J. Clin. Investig. 2015;125:3642&#x2013;3656. doi: 10.1172/JCI80437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI80437</ArticleId><ArticleId IdType="pmc">PMC4588275</ArticleId><ArticleId IdType="pubmed">26301815</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchet D., Garcia C., Deboux C., Nait-Oumesmar B., Baron-Van Evercooren A. Human neural progenitors from different foetal forebrain regions remyelinate the adult mouse spinal cord. Brain. 2011;134:1168&#x2013;1183. doi: 10.1093/brain/awr030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr030</ArticleId><ArticleId IdType="pubmed">21459827</ArticleId></ArticleIdList></Reference><Reference><Citation>Marteyn A., Sarrazin N., Yan J., Bachelin C., Deboux C., Santin M.D., Gressens P., Zujovic V., Baron-Van Evercooren A. Modulation of the Innate Immune Response by Human Neural Precursors Prevails over Oligodendrocyte Progenitor Remyelination to Rescue a Severe Model of Pelizaeus-Merzbacher Disease. Stem Cells. 2016;34:984&#x2013;996. doi: 10.1002/stem.2263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/stem.2263</ArticleId><ArticleId IdType="pubmed">26676415</ArticleId></ArticleIdList></Reference><Reference><Citation>Gumpel M., Lachapelle F., Gansmuller A., Baulac M., Baron van Evercooren A., Baumann N. Transplantation of human embryonic oligodendrocytes into shiverer brain. Ann. N. Y. Acad. Sci. 1987;495:71&#x2013;85. doi: 10.1111/j.1749-6632.1987.tb23666.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.1987.tb23666.x</ArticleId><ArticleId IdType="pubmed">3300467</ArticleId></ArticleIdList></Reference><Reference><Citation>Windrem M.S., Schanz S.J., Guo M., Tian G.F., Washco V., Stanwood N., Rasband M., Roy N.S., Nedergaard M., Havton L.A., et al. Neonatal chimerization with human glial progenitor cells can both remyelinate and rescue the otherwise lethally hypomyelinated shiverer mouse. Cell Stem Cell. 2008;2:553&#x2013;565. doi: 10.1016/j.stem.2008.03.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2008.03.020</ArticleId><ArticleId IdType="pmc">PMC3358921</ArticleId><ArticleId IdType="pubmed">18522848</ArticleId></ArticleIdList></Reference><Reference><Citation>Procaccini C., Santopaolo M., Faicchia D., Colamatteo A., Formisano L., de Candia P., Galgani M., De Rosa V., Matarese G. Role of metabolism in neurodegenerative disorders. Metabolism. 2016;65:1376&#x2013;1390. doi: 10.1016/j.metabol.2016.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2016.05.018</ArticleId><ArticleId IdType="pubmed">27506744</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty G., Ledeen R. Fatty acid synthesizing enzymes intrinsic to myelin. Brain Res. Mol. Brain Res. 2003;112:46&#x2013;52. doi: 10.1016/S0169-328X(03)00033-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0169-328X(03)00033-0</ArticleId><ArticleId IdType="pubmed">12670701</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmerly C.A., Weiss W.P. Effects of supplemental dietary biotin on performance of Holstein cows during early lactation. J. Dairy Sci. 2001;84:498&#x2013;506. doi: 10.3168/jds.S0022-0302(01)74500-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.3168/jds.S0022-0302(01)74500-6</ArticleId><ArticleId IdType="pubmed">11233035</ArticleId></ArticleIdList></Reference><Reference><Citation>Abiraman K., Pol S.U., O&#x2019;Bara M.A., Chen G.D., Khaku Z.M., Wang J., Thorn D., Vedia B.H., Ekwegbalu E.C., Li J.X., et al. Anti-muscarinic adjunct therapy accelerates functional human oligodendrocyte repair. J. Neurosci. 2015;35:3676&#x2013;3688. doi: 10.1523/JNEUROSCI.3510-14.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3510-14.2015</ArticleId><ArticleId IdType="pmc">PMC4464275</ArticleId><ArticleId IdType="pubmed">25716865</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu J., Banki A., Wu Q., Nishiyama A. Increased NG2(+) glial cell proliferation and oligodendrocyte generation in the hypomyelinating mutant shiverer. Glia. 2004;48:51&#x2013;63. doi: 10.1002/glia.20055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.20055</ArticleId><ArticleId IdType="pubmed">15326615</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchet D., Baron-Van Evercooren A. In search of human oligodendroglia for myelin repair. Neurosci. Lett. 2009;456:112&#x2013;119. doi: 10.1016/j.neulet.2008.09.086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2008.09.086</ArticleId><ArticleId IdType="pubmed">19429145</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietz K.C., Polanco J.J., Pol S.U., Sim F.J. Targeting human oligodendrocyte progenitors for myelin repair. Exp. Neurol. 2016;283:489&#x2013;500. doi: 10.1016/j.expneurol.2016.03.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2016.03.017</ArticleId><ArticleId IdType="pmc">PMC5666574</ArticleId><ArticleId IdType="pubmed">27001544</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkpatrick L.L., Witt A.S., Payne H.R., Shine H.D., Brady S.T. Changes in microtubule stability and density in myelin-deficient shiverer mouse CNS axons. J. Neurosci. 2001;21:2288&#x2013;2297. doi: 10.1523/JNEUROSCI.21-07-02288.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.21-07-02288.2001</ArticleId><ArticleId IdType="pmc">PMC6762390</ArticleId><ArticleId IdType="pubmed">11264304</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady S.T., Witt A.S., Kirkpatrick L.L., de Waegh S.M., Readhead C., Tu P.H., Lee V.M. Formation of compact myelin is required for maturation of the axonal cytoskeleton. J. Neurosci. 1999;19:7278&#x2013;7288. doi: 10.1523/JNEUROSCI.19-17-07278.1999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.19-17-07278.1999</ArticleId><ArticleId IdType="pmc">PMC6782532</ArticleId><ArticleId IdType="pubmed">10460234</ArticleId></ArticleIdList></Reference><Reference><Citation>Meschkat M., Steyer A.M., Weil M.T., Kusch K., Jahn O., Piepkorn L., Agui-Gonzalez P., Phan N.T.N., Ruhwedel T., Sadowski B., et al. White matter integrity in mice requires continuous myelin synthesis at the inner tongue. Nat. Commun. 2022;13:1163. doi: 10.1038/s41467-022-28720-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-28720-y</ArticleId><ArticleId IdType="pmc">PMC8897471</ArticleId><ArticleId IdType="pubmed">35246535</ArticleId></ArticleIdList></Reference><Reference><Citation>Windrem M.S., Schanz S.J., Morrow C., Munir J., Chandler-Militello D., Wang S., Goldman S.A. A competitive advantage by neonatally engrafted human glial progenitors yields mice whose brains are chimeric for human glia. J. Neurosci. 2014;34:16153&#x2013;16161. doi: 10.1523/JNEUROSCI.1510-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1510-14.2014</ArticleId><ArticleId IdType="pmc">PMC4244478</ArticleId><ArticleId IdType="pubmed">25429155</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams K.L., Dahl K.D., Gallo V., Macklin W.B. Intrinsic and extrinsic regulators of oligodendrocyte progenitor proliferation and differentiation. Semin. Cell Dev. Biol. 2021;116:16&#x2013;24. doi: 10.1016/j.semcdb.2020.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcdb.2020.10.002</ArticleId><ArticleId IdType="pmc">PMC9302595</ArticleId><ArticleId IdType="pubmed">34110985</ArticleId></ArticleIdList></Reference><Reference><Citation>Nave K.A., Werner H.B. Ensheathment and Myelination of Axons: Evolution of Glial Functions. Annu. Rev. Neurosci. 2021;44:197&#x2013;219. doi: 10.1146/annurev-neuro-100120-122621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-neuro-100120-122621</ArticleId><ArticleId IdType="pubmed">33722070</ArticleId></ArticleIdList></Reference><Reference><Citation>Nave K.A., Werner H.B. Myelination of the nervous system: Mechanisms and functions. Annu. Rev. Cell Dev. Biol. 2014;30:503&#x2013;533. doi: 10.1146/annurev-cellbio-100913-013101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-cellbio-100913-013101</ArticleId><ArticleId IdType="pubmed">25288117</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinkai Y., Rathbun G., Lam K.P., Oltz E.M., Stewart V., Mendelsohn M., Charron J., Datta M., Young F., Stall A.M., et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell. 1992;68:855&#x2013;867. doi: 10.1016/0092-8674(92)90029-C.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(92)90029-C</ArticleId><ArticleId IdType="pubmed">1547487</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>